Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Dr. Lal PathLabs is a leading diagnostic healthcare service provider in India, offering over 5000 tests through an extensive national network of labs and service centers.
Despite industry challenges, the company achieved a 10.6% YoY increase in revenue for Q3 FY26, underscoring its ability to sustain growth through strategic moves like network expansion and introduction of new tests.
The launch of Sovaaka, a personalized preventive healthcare platform, has been pivotal, marking a shift towards preventive and predictive healthcare services, leveraging advanced diagnostics and AI technology.
Significant strides in increasing high-end diagnostic portfolios signal the company's focus on capturing a larger share of the preventive and specialty diagnostics markets, particularly through specialized centers and new test introductions.
Dr. Lal PathLabs' financial resilience is evident from its robust EBITDA margins and strategic reinvestment in growth areas like high-end radiology, demonstrating both operational efficiency and strategic foresight.
Healthcare Services
Healthcare Service Provider
27,502 Cr
Low Risk
54.5
58.9
3.2
10.8
1,771.30
1,272.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockDr Lal Pathlabs Ltd (LALPATHLAB) is currently trading at 1,640.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dr. Lal PathLabs is a leading diagnostic healthcare service provider in India, offering over 5000 tests through an extensive national network of labs and service centers. Despite industry challenges, the company achieved a 10.6% YoY increase in revenue for Q3 FY26, underscoring its ability to sustain growth through strategic moves like network expansion and introduction of new tests. The launch of Sovaaka, a personalized preventive healthcare platform, has been pivotal, marking a shift towards preventive and predictive healthcare services, leveraging advanced diagnostics and AI technology. Significant strides in increasing high-end diagnostic portfolios signal the company's focus on capturing a larger share of the preventive and specialty diagnostics markets, particularly through specialized centers and new test introductions. Dr. Lal PathLabs' financial resilience is evident from its robust EBITDA margins and strategic reinvestment in growth areas like high-end radiology, demonstrating both operational efficiency and strategic foresight.
Over the past 52 weeks, Dr Lal Pathlabs Ltd has traded between a low of ₹1,272.00 and a high of ₹1,771.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dr Lal Pathlabs Ltd has a market capitalization of approximately 27,136.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dr Lal Pathlabs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 53.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 27,136.36 Cr, Dr Lal Pathlabs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dr Lal Pathlabs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dr Lal Pathlabs Ltd is 53.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock rose 11% to ₹1,803.60 after the company reported Q4 FY26 revenue of ₹703 crore, up 16.6% year-on-year, driven mainly by higher sample volumes.
Consolidated revenue was Rs 703 crore (up 16.6% YoY) and reported net profit was Rs 132 crore (down 15.1% YoY).
The stock hit the upper circuit after Q4 FY26 updates showed 16.6% year-on-year revenue growth and brokerages reiterated positive views with revised target prices.
Q2 revenue rose 10.7% YoY to INR 731.00 crore, and PAT increased 16.4% YoY to INR 152.00 crore.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1625.95 | 27,136 Cr | 53.76 | 10.82 | 1.51 | 20.13 | 25.56 | 16.20 | ||
1287.40 | 13,211 Cr | 76.38 | 13.80 | 0.16 | 18.07 | 19.27 | 11.48 | ||
525.05 | 10,894 Cr | 57.33 | 7.20 | 0.95 | 12.56 | 16.25 | 8.94 | ||
534.50 | 8,526 Cr | 52.29 | 16.63 | 2.61 | 27.85 | 33.90 | 21.79 | ||
717.60 | 7,133 Cr | 92.83 | 6.39 | 0.00 | 6.88 | 13.18 | 5.22 | ||
539.25 | 1,749 Cr | 17.24 | 1.78 | 0.37 | 10.35 | 10.42 | 5.56 | ||
267.50 | 1,395 Cr | 43.33 | 5.70 | 0.19 | 13.15 | 14.38 | 7.01 | ||
| Median: 7 Co. | — | 539.25 | 8,526 Cr | 53.76 | 7.20 | 0.37 | 13.15 | 16.25 | 8.94 |
Wholly-owned subsidiary
Dr. Lal PathLabs incorporated DR LAL PATHLABS FZCO in Dubai on June 12, 2026 (Certificate from DMCC); subscribed share capital AED 19,135,000 (19,135 shares of AED 1,000) to pursue diagnostics and allied investments.
Subsidiary incorporation
Dr. Lal PathLabs has incorporated a 100% owned subsidiary, DR LAL PATHLABS FZCO, in DMCC, Dubai on June 12, 2026, subscribing to AED 19,135,000 (19,135 shares of AED 1,000) to pursue diagnostics investments and tie-ups.
Bearish
5
Neutral
6
Bullish
3
Bearish
5
Neutral
6
Bullish
35
Bearish
0
Neutral
0
Bullish
32
